Valuation: BioRestorative Therapies, Inc.

Market Cap 7.06M 6.2M 5.78M 5.31M 9.95M 676M 10.12M 68.34M 26.77M 334M 26.49M 25.92M 1.16B P/E 2026 *
-0.56x
P/E 2027 * -0.68x
Enterprise Value 7.06M 6.2M 5.78M 5.31M 9.95M 676M 10.12M 68.34M 26.77M 334M 26.49M 25.92M 1.16B EV / Sales 2026 *
5.02x
EV / Sales 2027 * 3.05x
Free-Float
87.87%
Yield 2026 *
-
Yield 2027 * -
1 day-3.75%
1 week-17.20%
Current month-29.10%
1 month-27.87%
3 months+14.57%
6 months-75.76%
Current year-77.31%
1 week 0.26
Extreme 0.26
0.35
1 month 0.26
Extreme 0.26
0.41
Current year 0.16
Extreme 0.1593
1.28
1 year 0.16
Extreme 0.1593
1.89
3 years 0.16
Extreme 0.1593
3.67
5 years 0.16
Extreme 0.1593
26.8
10 years 0.16
Extreme 0.1593
20,040
Manager TitleAgeSince
Chief Executive Officer 55 16/11/2020
Director of Finance/CFO 59 04/11/2021
Investor Relations Contact - -
Director TitleAgeSince
Chairman 55 16/11/2020
Director/Board Member 61 29/10/2021
Director/Board Member 28 12/06/2026
Date Insider Type Main position Quantity % Market Cap.
10/6/25 A Free

Chief Technology Officer

23,438 0.2938%
10/6/25 A Free

Chief Executive Officer

27,344 0.3427%
2/14/25 A Other

Director

52,632 0.7606%
Change 5-day change 1-year change 3-year change Capi.($)
-3.75%-17.20%-83.54%-90.58% 7.06M
-2.25%+2.44%+53.17%+64.57% 56.19B
-1.32%-0.97%+38.41%+77.52% 54.83B
+1.49%+0.31%-19.82%-11.95% 23.04B
-0.57%-2.70%+0.17%+410.44% 22.7B
-0.21%+0.84%+22.48%-7.92% 20.23B
0.00%+3.30%+28.01%-29.07% 17.83B
-0.97%+0.89%+37.28%+539.62% 15.65B
-6.69%-5.11%+166.00%+304.89% 15.24B
+1.25%+1.76%+23.93%+188.32% 14.03B
Average -1.30%-1.34%+26.61%+144.58% 23.97B
Weighted average by Cap. -1.17%+0.42%+37.72%+133.37%

Financials

2026 *2027 *
Net sales 1.4M 1.23M 1.15M 1.06M 1.98M 135M 2.01M 13.6M 5.33M 66.56M 5.27M 5.16M 230M 2.31M 2.03M 1.9M 1.74M 3.26M 222M 3.32M 22.39M 8.77M 110M 8.68M 8.49M 379M
Net income -13.52M -11.88M -11.08M -10.18M -19.07M -1.3B -19.39M -131M -51.3M -641M -50.77M -49.67M -2.22B -15.56M -13.67M -12.75M -11.71M -21.95M -1.49B -22.31M -151M -59.02M -737M -58.41M -57.14M -2.55B
Net Debt - -
Logo BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
Employees
14
Date Price Change Volume
28/07/26 $0.2666 -3.75% 505,593
27/07/26 $0.2770 -4.48% 687,006
24/07/26 $0.2900 -7.17% 300,507
23/07/26 $0.3124 -1.45% 130,402
22/07/26 $0.3170 -1.71% 136,851
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.2666USD
Average target price
8.000USD
Spread / Average Target
+2,900.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRTX Stock